Insmed (INSM) to Release Quarterly Earnings on Friday

Share on StockTwits

Insmed (NASDAQ:INSM) will release its earnings data before the market opens on Friday, February 22nd. Analysts expect Insmed to post earnings of ($1.10) per share for the quarter.

Shares of NASDAQ:INSM opened at $27.07 on Tuesday. Insmed has a 52-week low of $11.31 and a 52-week high of $31.58. The company has a market capitalization of $2.09 billion, a P/E ratio of -9.37 and a beta of 2.91. The company has a current ratio of 10.06, a quick ratio of 10.06 and a debt-to-equity ratio of 1.07.

In other Insmed news, Director Alfred Altomari sold 5,500 shares of the stock in a transaction on Thursday, January 10th. The stock was sold at an average price of $22.50, for a total transaction of $123,750.00. Following the sale, the director now owns 42,442 shares of the company’s stock, valued at approximately $954,945. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.88% of the stock is currently owned by company insiders.

Several brokerages recently issued reports on INSM. JMP Securities raised Insmed from a “market perform” rating to an “outperform” rating and set a $40.00 price objective on the stock in a research note on Friday. ValuEngine cut Insmed from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 5th. Zacks Investment Research raised Insmed from a “hold” rating to a “buy” rating and set a $28.00 price objective on the stock in a research note on Tuesday, January 22nd. Goldman Sachs Group raised Insmed from a “neutral” rating to a “buy” rating and increased their target price for the company from $29.00 to $35.00 in a research report on Thursday, January 17th. Finally, Canaccord Genuity increased their target price on Insmed from $20.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, January 15th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Insmed presently has an average rating of “Buy” and a consensus price target of $34.38.

TRADEMARK VIOLATION NOTICE: This story was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/4163374/insmed-insm-to-release-quarterly-earnings-on-friday.html.

Insmed Company Profile

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex.

Featured Article: What is Compound Annual Growth Rate (CAGR)?

Earnings History for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Arconic Inc  Position Trimmed by LPL Financial LLC
Arconic Inc Position Trimmed by LPL Financial LLC
Heartland Financial USA Inc  Expected to Announce Quarterly Sales of $135.23 Million
Heartland Financial USA Inc Expected to Announce Quarterly Sales of $135.23 Million
Callon Petroleum  Holdings Increased by PNC Financial Services Group Inc.
Callon Petroleum Holdings Increased by PNC Financial Services Group Inc.
Cipher Capital LP Buys New Holdings in Fortune Brands Home & Security Inc
Cipher Capital LP Buys New Holdings in Fortune Brands Home & Security Inc
Nektar Therapeutics  Shares Sold by Gotham Asset Management LLC
Nektar Therapeutics Shares Sold by Gotham Asset Management LLC
Cipher Capital LP Takes $906,000 Position in New York Times Co
Cipher Capital LP Takes $906,000 Position in New York Times Co


© 2006-2019 Ticker Report